Sionna Therapeutics, Inc. is an innovative biotechnology company focused on developing advanced therapies for neurodegenerative disorders, notably Alzheimer's and Parkinson's diseases linked to protein misfolding. The company boasts a robust pipeline supported by proprietary technologies aimed at addressing substantial unmet medical needs within this urgent therapeutic space. Through strategic partnerships and a strong commitment to research and development, Sionna is well-positioned to become a leader in the biopharmaceutical sector, dedicated to enhancing patient outcomes and overall quality of life with its groundbreaking neurological treatments.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-108.84M |
| Operating Margin | 0.00% |
| Return on Equity | -32.30% |
| Return on Assets | -21.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $5.88 |
| Price-to-Book | 0.56 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $45.15M |
| Float | $20.47M |
| % Insiders | 7.88% |
| % Institutions | 101.53% |
Volatility is currently expanding
WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to develop novel medicines for cystic fibrosis (CF), today announced that management will participate in fireside chats at the following upcoming investor events:
Sionna Therapeutics, Inc. (SION) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the "Company") (NASDAQ: SION). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the "Company") (NASDAQ: SION).
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION).
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. ("Sionna" or the "Company") (NASDAQ: SION).
Sionna set to reduce its workforce by 46% after SION-719 fails a key CF study, shifting focus to SION-451 + SION-2222.
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Sionna Therapeutics, Inc. (SION) Discusses Post-Hoc Analysis of PreciSION CF Trial and Advancement of Dual Combination Program Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SION and any ticker you trade — then tracks every position and per-strategy win rate.
